Status:
NOT_YET_RECRUITING
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Multiple Myeloma (MM)
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, non-interventional study aims to characterize the molecular and cellular mechanisms underlying the response and resistance of multiple myeloma (MM) patients to bispecific antibodies ...
Detailed Description
The study protocol outlines a prospective, non-interventional research initiative at Tel Aviv Sourasky Medical Center to investigate molecular mechanisms of response and resistance to bispecific antib...
Eligibility Criteria
Inclusion
- Diagnosed with multiple myeloma Candidate for BisAb, CAR-T, or other myeloma therapy Mentally competent and able to sign informed consent
Exclusion
- Unable to undergo bone marrow sampling Pregnant women Minors (\<18), incapacitated, or legally incompetent
Key Trial Info
Start Date :
March 19 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 3 2031
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06888856
Start Date
March 19 2025
End Date
March 3 2031
Last Update
March 21 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.